Regeneron Pharmaceuticals Inc. (Nasdaq: REGN)

https://www.regeneron.com

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. *

	Start	1988-01-01 established
	End	1998-07-27 existent
	Group	Regeneron (Group)
	Industry	biopharmaceutical

	Street	777 Old Saw Mill River Rd.
	City	10591 Tarrytown, NY
	Tel	+1-919-345-7400
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Regeneron Pharmaceuticals, Inc.. (4/19/22). "Press Release: Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types". Tarrytown, NY & Cambridge, MA.

		Record changed: 2023-07-10